ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Agilent 2023 Early Career Professor Award Presented to Ajit Divakaruni

UCLA scientist recognized for research developing live cell analytical tools to advance bioprocess and biomanufacturing applications

Agilent Technologies Inc. (NYSE: A) announced today that Ajit Divakaruni, Ph.D., has received the Agilent 2023 Early Career Professor Award. Dr. Divakaruni is an Assistant Professor in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA).

The 2023 award focused on contributions to developing live cell analytical tools to identify and measure novel critical quality attributes to advance biomanufacturing applications. Dr. Divakaruni’s interest in developing cell-based metabolic assays to guide CAR-T cell manufacturing and bioprocess development strongly aligns with Agilent’s increasing attention to developing solutions that support immunotherapies and other cell-based therapies.

The Divakaruni lab focuses on how energy metabolism and metabolic flexibility – the ability to switch between sugar, amino acid, and fatty acid oxidation in response to biological cues – can control cell function and fate. This research aims to discover novel regulatory points of metabolism and develop mitochondrial proteins and pathways as therapeutic drug targets.

“I am honored and beyond grateful to have been selected as this year’s recipient of the Agilent Early Career Professor Award. It is a privilege to be recognized for our work in developing mitochondrial and metabolic assays to help guide early-stage drug development and inform cell-based therapeutics,” said Dr. Divakaruni. “Real-time, microplate-based assays have been central to the resurgent interest in cellular metabolism, and these will continue to be at the forefront as we continue to learn even more about how mitochondria and metabolism can shape cell function.”

“Dr. Divakaruni’s innovative research is expanding the basic science of understanding how cell metabolism can be a driver of cell function and fate and has also made critical contributions to live cell measurement tools that elevate researchers in this field,” said Chong Wing Yung, associate director of University Relations and External Research at Agilent. “We are proud to further engage with Dr. Divakaruni and support his future research endeavors, including analytical technologies for bioprocess and biomanufacturing applications.”

Dr. Divakaruni’s current work includes studying the crosstalk between metabolism and innate immunity and examining how adjusting the balance between sugar, fat, and amino acid oxidation can affect metabolic and neurological disease. The development and refinement of functional mitochondrial measurements are central to this work, and the Divakaruni lab emphasizes protocols and ‘roadmap’ manuscripts that may assist other researchers as they plan their experiments.

Future directions of Dr. Divakaruni’s research include developing novel cell-based metabolic assays to guide CAR-T cell bioprocess development and biomanufacturing. As critical quality attributes for producing efficacious cell therapies are still poorly defined, his expertise in cell metabolism and cell analysis will play a key role in helping to define these standards.

The Agilent Early Career Professor Award is an annual program that recognizes and supports promising research from professors who, early in their careers, show outstanding potential for future research in areas of importance to the communities Agilent serves. This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers. Further information about the program is available at Agilent.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.22
+4.06 (1.77%)
AAPL  278.85
+1.30 (0.47%)
AMD  217.53
+3.29 (1.54%)
BAC  53.65
+0.66 (1.25%)
GOOG  320.12
-0.16 (-0.05%)
META  647.95
+14.34 (2.26%)
MSFT  492.01
+6.51 (1.34%)
NVDA  177.00
-3.26 (-1.81%)
ORCL  201.95
-3.01 (-1.47%)
TSLA  430.17
+3.59 (0.84%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.